Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367377 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3209590 in Participants With Type 2 Diabetes
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT03367377 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 70 participants.
The verdict
NCT03367377, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of LY3209590 when given by injection under the skin to participants with type 2 diabetes. It will also investigate how the body processes the study drug and the effect of the study drug on blood sugar levels. Information about any side effects will be documented. This study will last approximately 17 weeks, not including screening. Screening is required within 4 weeks prior to the start of the study.
Interventions
- DRUG LY3209590
- DRUG Insulin Glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2018-01-03 |
| Est. Completion | 2018-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03367377
The ClinicalTrials.gov registry entry for NCT03367377 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LY3209590 is the first listed.
NCT03367377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03367377 about?
NCT03367377 is a clinical study titled "A Study of LY3209590 in Participants With Type 2 Diabetes". This study will evaluate the safety and tolerability of LY3209590 when given by injection under the skin to participants with type 2 diabetes. It will also investigate how the body processes the study drug and the effect of the study drug on blood sugar levels. Information about any side effects wil...
What is the current status of trial NCT03367377?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2018-01-03. Estimated completion is 2018-10-03.
What interventions are being tested in trial NCT03367377?
The interventions under investigation include: LY3209590 (DRUG), Insulin Glargine (DRUG).
Who is sponsoring clinical trial NCT03367377?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.